MedTrace Logo

Registry for Prostate Cancer Focal Therapy

NCT07792590 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-08-28

No results posted yet for this study

Summary

Whole gland therapy (radical prostatectomy and radiotherapy) has been the conventional treatment for localized prostate cancer, but randomized controlled trials have not demonstrated survival benefits compared with watchful waiting or active surveillance. Whole gland therapy is also associated with significant long-term sequelae including urinary incontinence, erectile dysfunction, irradiation cystitis, and proctitis. Focal therapy has emerged as an alternative treatment modality, yet more data are needed to ensure its safety and efficacy. This is a prospective database/registry study designed to record all pre-operative, intra-operative, and post-operative parameters for patients undergoing focal therapies for prostate cancer, including but not limited to cryotherapy, high-intensity focused ultrasound (HIFU), focal laser therapy (FLA), irreversible electroporation (IRE), targeted microwave ablation (TMA). All patients who have undergone focal therapy at the Department of Surgery, Queen Mary Hospital for prostate cancer will be invited to participate, except those incapable of providing written informed consent. The primary outcome is the surgical outcomes (complications and effectiveness) of focal therapies. Secondary outcomes include identification of risk factors for treatment-related complications, provision of a readily available dataset for subsequent research, and identification of the best treatment allocation for prostate cancer patients. An estimated 200 patients will be included, with data collection from study start until 31 March 2030.

Conditions

Interventions

PROCEDURE

Focal Therapy for Prostate Cancer

Focal ablation for prostate cancer using one of the following modalities: cryotherapy, high-intensity focused ultrasound (HIFU), focal laser therapy (FLA), or irreversible electroporation (IRE), targeted microwave ablation (TMA). The specific modality is selected based on clinical indication. Data on pre-operative, intra-operative, and post-operative parameters are collected prospectively in a registry. Primary outcome is surgical outcomes (complications and effectiveness). Secondary outcomes include identification of risk factors for treatment-related complications, provision of a readily available dataset for subsequent research, and identification of the best treatment allocation.

Sponsors & Collaborators

  • Queen Mary Hospital, Hong Kong

    collaborator OTHER

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Shung Lai John Leung · The University of Hong Kong, Hospital Authority

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2030-11-30
Completion
2031-02-28

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07792590 on ClinicalTrials.gov